Comparison of Blood-Brain Barrier Models for in vitro Biological Analysis: One Cell Type vs Three Cell Types.
暂无分享,去创建一个
Yang Song | Yuehe Lin | Dan Du | P. Dutta | Xiaoli Cai
[1] Yang Song,et al. In Vitro Study of Receptor-Mediated Silica Nanoparticles Delivery across Blood-Brain Barrier. , 2017, ACS applied materials & interfaces.
[2] J. Berwick,et al. LRP-1-mediated intracellular antibody delivery to the Central Nervous System , 2015, Scientific Reports.
[3] Krunal K. Mehta,et al. Biomineralized anisotropic gold microplate-macrophage interactions reveal frustrated phagocytosis-like phenomenon: a novel paclitaxel drug delivery vehicle. , 2014, ACS applied materials & interfaces.
[4] K. Dawson,et al. Imaging approach to mechanistic study of nanoparticle interactions with the blood-brain barrier. , 2014, ACS nano.
[5] Yoshinobu Manome,et al. Cell-Based in Vitro Blood–Brain Barrier Model Can Rapidly Evaluate Nanoparticles’ Brain Permeability in Association with Particle Size and Surface Modification , 2014, International journal of molecular sciences.
[6] Peter C. Searson,et al. The blood-brain barrier: an engineering perspective , 2013, Front. Neuroeng..
[7] Dong Yun Lee,et al. In vivo biodistribution and toxicology of carboxylated graphene quantum dots. , 2013, ACS nano.
[8] Luca Cucullo,et al. In vitro blood-brain barrier models: current and perspective technologies. , 2012, Journal of pharmaceutical sciences.
[9] D. Emerich,et al. Biomaterial-based technologies for brain anti-cancer therapeutics and imaging. , 2010, Biochimica et biophysica acta.
[10] Rongqin Huang,et al. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo , 2010, Brain Research Bulletin.
[11] Joanna M. Wardlaw,et al. Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis , 2009, Neurobiology of Aging.
[12] Wei Lu,et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[13] Chen Jiang,et al. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. , 2008, Biomaterials.
[14] E. Hansson,et al. Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.
[15] T. Davis,et al. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.
[16] G. Savettieri,et al. Permeability properties of a three‐cell type in vitro model of blood‐brain barrier , 2005, Journal of cellular and molecular medicine.
[17] K. Hayashi,et al. Effects of hypoxia on endothelial/pericytic co-culture model of the blood–brain barrier , 2004, Regulatory Peptides.
[18] D. Begley. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.
[19] M. Nedergaard,et al. The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.
[20] P. Couvreur,et al. Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.
[21] E. Ezan,et al. A co-culture-based model of human blood–brain barrier: application to active transport of indinavir and in vivo–in vitro correlation , 2002, Brain Research.
[22] C. Lohmann,et al. Predicting Blood-Brain Barrier Permeability of Drugs: Evaluation of Different In Vitro Assays , 2002, Journal of drug targeting.
[23] J. Neumaier,et al. A new model of the blood--brain barrier: co-culture of neuronal, endothelial and glial cells under dynamic conditions. , 1999, Neuroreport.
[24] L. Rubin,et al. A cell culture model of the blood-brain barrier , 1991, The Journal of cell biology.